美国神经系统疾病患病率估算新方法:以多发性硬化为例
多发性硬化患病率工作组通过SWOT分析评估了三种估算多发性硬化患病率的方法,提出一种新的四步法:识别覆盖公私保险人群的行政健康索赔数据库、开发并验证高准确度多发性硬化病例发现算法、应用病例定义算法估算各人群患病率、按各保险部分参保人数加权合并为全美患病率估计。
要点
- 提出四步法估算美国多发性硬化患病率,基于行政健康索赔数据库。
- 方法核心包括开发可标准化应用的高准确度多发性硬化病例发现算法。
- 按各保险部分参保人数加权合并各人群患病率估计。
核心结论
- 通过解决方法学挑战并提出新方法,有望惠及研究缺乏全国患病率估计的神经系统疾病和其他慢性病的科学家。
研究设计与样本
- 对三种估算多发性硬化患病率的方法进行SWOT分析:基于人群的多发性硬化登记、全国概率健康调查、行政健康索赔数据库分析。
主要发现
- 提出新的四步法估算美国多发性硬化患病率,第一步识别覆盖美国公私保险人群的行政健康索赔数据库。
- 第二步开发并验证可标准化应用于所有数据库的高准确度多发性硬化病例发现算法。
- 第三步应用病例定义算法估算各人群多发性硬化患病率。
- 第四步按各健康保险部分参保人数加权,将各人群患病率估计合并为全美患病率单一估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era. METHODS: We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence. RESULTS: We developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment. CONCLUSIONS: By addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist.
引用
- Nelson LM, Wallin MT, Marrie RA, et al. A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS. Neurology. 2019. PMID: 30770422. doi:10.1212/WNL.0000000000007044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。